Previous 10 | Next 10 |
SEATTLE, WA and VANCOUVER, BC / ACCESSWIRE / January 7, 2021 / Achieve Life Sciences, Inc. (NASDAQ:ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation, today announced that John Bencich, Chief Execu...
Achieve Life Sciences, Inc. Announces Closing of $17.3 Million Underwritten Public Offering, Including Full Exercise of Overallotment Option SEATTLE and VANCOUVER, B.C. , Dec. 7, 2020 /PRNewswire/ -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage p...
Achieve Life Sciences Announces Pricing of $15 Million Public Offering SEATTLE and VANCOUVER, B.C. , Dec. 3, 2020 /PRNewswire/ -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commerci...
Achieve Life Sciences (ACHV) to offer 1.5M common shares in a public offering, underwriters have an option to purchase up to an additional 225k shares.Price, other terms are yet to be decided.Shares are down 4.4% in premarket For further details see: Achieve Life Sciences...
Achieve Life Sciences, Inc. (ACHV) Q3 2020 Earnings Conference Call November 12, 2020 16:30 ET Company Participants Jaime Xinos - Executive Vice President, Commercial John Bencich - Chief Executive Officer Cindy Jacobs - President and Chief Medical Officer Jerry Wan - Principal Accounting Off...
Achieve Life Sciences (ACHV): Q3 GAAP EPS of -$1.14 beats by $0.17.Cash, cash equivalents, and restricted cash of $22.4MPress Release For further details see: Achieve Life Sciences EPS beats by $0.17
Achieve Reports Financial Results for Third Quarter 2020 and Provides Corporate and Cytisinicline Development Update Canada NewsWire SEATTLE and VANCOUVER, BC, Nov. 12, 2020 SEATTLE and VANCOUVER, BC , Nov. 12, 2020 /CNW/ -- Achieve Life Sciences, Inc. (N...
Achieve Life Sciences to Announce Third Quarter 2020 Financial Results and Host Conference Call and Webcast on November 12, 2020 PR Newswire SEATTLE and VANCOUVER, BC, Oct. 29, 2020 SEATTLE and VANCOUVER, BC , Oct. 29, 2020 /PRNewswire/ -- Achieve Life Sc...
Achieve Life Sciences to Host Smoking Cessation Key Opinion Leader Virtual Roundtable on November 17th, 2020 PR Newswire SEATTLE and VANCOUVER, BC, Oct. 27, 2020 SEATTLE and VANCOUVER, BC, Oct. 27, 2020 /PRNewswire/ --Achieve Life Sciences, Inc. (NASDAQ:...
SEATTLE, WA and VANCOUVER, BC / ACCESSWIRE / October 8, 2020 / Achieve Life Sciences, Inc. (NASDAQ:ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced that it...
News, Short Squeeze, Breakout and More Instantly...
Achieve Life Sciences Inc. Company Name:
ACHV Stock Symbol:
NASDAQ Market:
Achieve Life Sciences Inc. Website:
– Two New Independent Directors, Stuart Duty and Andrew Saik, Appointed – Third New Independent Director to Be Appointed to Board in Near Term MONTREAL and CHARLOTTE, N.C., July 15, 2024 (GLOBE NEWSWIRE) -- Milestone ® Pharmaceuticals Inc. (Nasdaq: MIST) (...
SEATTLE and VANCOUVER, British Columbia, July 09, 2024 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, today announced that...
SEATTLE and VANCOUVER, British Columbia, July 01, 2024 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, announced that the c...